Hemophilia Treatment Market Size & Share Forecast 2021-2027

The hemophilia treatment market was valued at US$ 12,797.36 million in 2019 and it is projected to reach US$ 20,507.92 million in 2027; it is expected to grow at a CAGR of 6.1% from 2020 to 2027.

Hemophilia is a hereditary genetic blood disorder that affects the capacity of the blood to clot due to the lack of a particular protein needed for blood clotting. The hemophilia is graded as Hemophilia A, Hemophilia B, and C. Many recombinant drugs, such as an antihemophilic factor or Factor VII, are injectable. Injectables are used before surgery to control and prevent bleeding episodes since the onset of action is rapid in comparison with other forms. The growth of the global hemophilia treatment market is attributed to the increasing prevalence of hemophilia and rise in favourable government initiatives. However, high cost related with hemophilia treatment is the major factor hindering the market growth.

The global hemophilia treatment market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.

Lucrative Regions for Global Hemophilia Treatment Market

Get more information on this report : Request Free Sample PDF

Market Insights

Increasing Prevalence of Hemophilia to Drive Global Hemophilia Treatment Market Growth

Hemophilia is a hereditary bleeding disorder that stops the blood from clotting normally. The primary symptom is uncontrolled, often spontaneous bleeding in different areas of the body. According to data from the National Hemophilia Foundation in 2020, Hemophilia A happens in 1 in 5,000 live male births. Hemophilia A is about four times as common as hemophilia B.  The number of people with hemophilia in the US is anticipated to be about 20,000 individuals since 1994. Moreover, the incidence of hemophilia is not known across the world; however, it is likely to be above 400,000 people. Almost 75% of people with hemophilia worldwide are either undiagnosed or receive disparate treatment.

In Italy, according to the data of the National Center for Biotechnology Information (NCBI) in 2017, the number of registered people with bleeding disorders increased from about 7,000 in 2000 to ~8,500 in 2011, and more than 11,000 in 2015. The trend is due to an upsurge in the number of patients who are recorded, mainly in those with vWD type 1, mild hemophilia, or other factor deficiencies.

The prevalence of the disease in the Asian countries is also increasing at an alarming rate. For instance, as per the report of Haemophilia Foundation Australia, 2020, more than 2,800 people were diagnosed with varying degrees of severity in hemophilia in the country.

Thus, increasing prevalence of hemophilia, high cases of under-diagnosed hemophilia cases, and improving healthcare infrastructure will eventually drive the growth of the market for hemophilia treatment in the forecast period.

Product -Based Insights

In terms of product, the global hemophilia treatment market is segmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, and antifibrinolytic agents. In 2019, the plasma-derived coagulation factor concentrates segment held largest share of the market. However, recombinant coagulation factor concentrates segment is estimated to register the highest CAGR during the forecast period.

Global Hemophilia Treatment Market, by Product – 2019 and 2027

Get more information on this report : Request Free Sample PDF

Disease-Based Insights

Based on disease, the global hemophilia treatment market is segmented into hemophilia A, hemophilia B, and hemophilia C. The hemophilia A segment held the largest market share in 2019. However, hemophilia B segment is estimated to grow at the fastest rate during the forecast period.

Treatment Type-Based Insights

Based on treatment type, the global hemophilia treatment market is segmented into prophylaxis and on-demand. The prophylaxis segment held the largest market share in 2019. However, the on-demand segment is estimated to grow at the fastest rate during the forecast period.

Therapy -Based Insights

Based on therapy, the global hemophilia treatment market is segmented into replacement therapy, ITI therapy, and gene therapy. The replacement therapy segment held the largest market share in 2019. Also, the same segment is estimated to register the highest CAGR during the forecast period.

End User-Based Insights

In terms of end user, the global hemophilia treatment market is segmented into hospitals & clinics, hemophilia treatment centers, and ambulatory surgical centers. The hospitals and clinics segment held the largest share of the market in 2019, and the same segment is estimated to grow at the fastest rate during the forecast period.

Strategic Insights

The global hemophilia treatment market players are adopting the product launch and expansion strategies to cater to changing customer demands worldwide, which also allows them to maintain their brand name globally.

Global Hemophilia Treatment Market – by Product

• Plasma Derived Coagulation Factor Concentrates
  • Factor VIII
  • Factor IX
  • Factor XII
  • Activated Prothrombin Complex Concentrate
  • Von Willebrand Factor
• Recombinant Coagulation Factor Concentrates
  • Factor VIII
  • Factor IX
• Antifibrinolytic Agents
• Desmopressin

Global Hemophilia Treatment Market – by Disease

• Hemophilia A
• Hemophilia B
• Hemophilia C

Global Hemophilia Treatment Market – by Treatment Type

• Prophylaxis
• On-demand

Global Hemophilia Treatment Market – by Therapy

• Replacement Therapy
• ITI Therapy
• Gene Therapy   

Global Hemophilia Treatment Market – by End- User

• Hospitals & Clinics
• Hemophilia Treatment Centers
• Ambulatory Surgical Centres

Global Hemophilia Treatment Market – by Geography

• North America

  • US
  • Canada
  • Mexico

• Europe

  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe

• Asia Pacific (APAC)

  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of APAC

• Middle East & Africa (MEA)

  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

• South America and Central America (SCAM)

  • Brazil
  • Argentina
  • Rest of SCAM

Company Profiles

• Bayer AG
• Sanofi
• F. Hoffmann-la Roche Ltd.
• Kedrion S.P.A.
• CSL Limited
• Biotest AG
• Pfizer Inc.
• Novo Nordisk A/S
• Octapharma AG
• Baxter International Inc.